personalized neoantigen ovarian cancer vaccine

{
  "id": "MLC-T-ONC-015980",
  "term": "personalized neoantigen ovarian cancer vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A peptide-based, personalized ovarian cancer therapeutic vaccine consisting of up to 20 neoantigens and peptides derived from patient-specific ovarian cancer immunogenic epitopes, combined with the immunostimulant poly-ICLC, with potential immunomodulating and antineoplastic activities. Upon administration, the personalized neoantigen ovarian cancer vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.",
  "synonyms": [
    "neoantigen-based ovarian cancer vaccine",
    "NeoVax ovarian cancer vaccine",
    "neoantigen-based ovarian cancer-poly-ICLC vaccine",
    "personalized neoantigen peptides ovarian cancer vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/personalized-neoantigen-ovarian-cancer-vaccine/"
}